



Next generation Needle-Free Live-Attenuated Vaccine for Broad Influenza Protection (led by Prof. Leo Poon)

Two Innovative Vaccine Technology Platforms


1. α 1,3-Galactosyltransferase Expressing LAIV



Inducing broadly protective and robust immune responses



2. Codon usage bias LAIV



Introduction of many silent mutations


Wild type (WT) Human virus
Human-like codon usage

Codon usage mutant LAIV


Human virus with
avian-like codon usage

- Attenuated in mammals
- Robust replication in avian


Virus Attenuation - Safety Profile



Durable Protection




Mucosal Immunity




Broad Flu Protection


Human H1N1



Human H3N2



Avian H5N1



Avian H7N9

